New Two-Pronged antibody trial targets Tough-to-Treat blood cancer
NCT ID NCT07432022
Summary
This early-stage study is testing a new drug called EMB-07, combined with other treatments, for aggressive B-cell non-Hodgkin lymphoma. It will enroll about 115 adults, including those with newly diagnosed disease and those whose cancer has returned or resisted previous treatment. The main goals are to find safe doses and see if the treatment helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.